PHASE-XS – A New Proprietary Database of Coherent Market Insights

PHASE-XS is a database developed by Coherent Market Insights, a market intelligence and consulting company. This database provides clinical information about phase 3 and phase 4 products for biologics and biosimilars. Information related to trial design, current phase, patent expiry, indication, technology, therapeutic category, approved indications, end point analysis, research locations, dosage, physician-administered or self-administered, route of administration, update, reimbursement, addressable patient population, and more of key data is included in the PHASE-XS.

Benefits of PHASE-XS:
• Identify the potential competitors in the future
• Identify target products for biosimilars through patent expiry of biologics
• Identify if there are any studies for the extension of indications of already approved products

• Identify the white spaces
• Identify the products with significant revenue opportunity
• Identify an ideal trial design with a competitive edge
• Actionable market forecast
• Identify the addressable patient pool

http://bit.ly/2EHFzSH

In the past few years, biopharmaceutical products are preferred over conventional pharmaceutical products for the treatment of various diseases, as it reacts highly specific against a target, and has less side effects and low toxicity. Lack of oral absorption was one of the major drawbacks of biologics, for which new delivery systems have been developed.

Companies engaged in the development of biosimilars and biologics will find this database very useful. Many biopharmaceutical companies are focusing on developing biosimilars due to increasing incidence of chronic diseases in the U.S., patent expiry of branded drugs, and the increasing support from regulatory agencies such as the U.S. FDA. The U.S. FDA has made approval process of biopharmaceutical products such as biosimilars easily accessible. In November 2018, UDENYCA, a biosimilar to Neulasta (pegfilgrastim) was approved by the FDA for subcutaneous use and in October 2018, a biosimilar to Adalimumab, Hyrimoz received approval from the FDA.

Therefore, to know more about biosimilar opportunity and the products that are under clinical trial, you can get access to PHASE-XS database through subscription service. Moreover, the data will be provided to the client in an excel sheet for better understanding. More information on PHASE-XS can be obtained through the link provided below.

About Coherent Market Insights:
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at

sales@coherentmarketinsights.com
https://www.coherentmarketinsights.com/phase-xs/

1001 4th Ave

This release was published on openPR.